David Hung, Nuvation Bio president and CEO (Nuvation Bio)

FDA places par­tial clin­i­cal hold on David Hung biotech af­ter cer­tain can­cer pa­tients ex­pe­ri­ence eye in­flam­ma­tion

Two and a half years af­ter set­ting out on an­oth­er for­ay in­to on­col­o­gy R&D, a biotech head­ed by David Hung — of Medi­va­tion fame — has run in­to its first set­back.

San Fran­cis­co-based Nu­va­tion Bio an­nounced ear­ly Mon­day the FDA placed a par­tial clin­i­cal hold on a Phase I dose-es­ca­la­tion study of NUV-422, its CDK in­hibitor pro­gram for cer­tain types of sol­id tu­mors. The tri­al be­gan en­rolling pa­tients in De­cem­ber 2020, and, ac­cord­ing to Nu­va­tion, re­searchers were in the mid­dle of ex­plor­ing dose es­ca­la­tion and defin­ing the max­i­mum dose tol­er­a­ble in pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.